Project

Skippain

Completed ยท 2018 until 2019

Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2018
End Date
2019
Financing
Industry
Study Design
This is a 24-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of secukinumab in controlling spinal pain in patients with axSpA. The study will consist of 2 treatment periods: a double-blind, placebo-controlled period from Baseline to Week 8 (i.e. Treatment Period 1) and a double-blind secukinumab treatment period from Week 8 to Week 24 (i.e. Treatment Period 2). At Baseline, patients will be randomized to either secukinumab 150 mg or placebo. At Week 8, patients will be re-randomized to 1 of 5 treatment arms to receive either secukinumab 150 mg or secukinumab 300 mg.
Keywords
spinal pain in patients with axSPA, secukinumab
Brief description/objective

SKIPPAIN (Speed of onset of SecuKinumab-Induced relief
from Pain in Patients with AxIal SpoNdyloarthritis)
A 24-week, randomized, double-blind, placebo-controlled,
multicenter study to evaluate the efficacy and safety of
secukinumab in controlling spinal pain in patients with
axial spondyloarthritis